A New Drug for Gastroesophageal Reflux Disease
HK inno.N announced on Feb. 3 that it has recently signed a contract with Malaysian pharmaceutical company Pharmaniaga Logistics Sdn Bhd to export K-CAB Tab. (ingredient: tegoprazan), a new drug for gastroesophageal reflux disease.
Through this contract, Pharmaniaga will have the right to exclusively distribute K-CAB Tab. in Malaysia for five years after the product launch. The contract amount was not disclosed in accordance with an agreement between the two companies.
Founded in 1994, Pharmaniaga is the largest pharmaceutical company in Malaysia. The company will be able to quickly expand its market share through aggressive sales after the launch of K-CAB Tab., industry analysts say.
By striking this deal, HK inno.N has exported K-Cab Tab. to all the six largest Southeast Asian economies -- Indonesia, Thailand, the Philippines, Vietnam, Singapore and Malaysia.
The size of Southeast Asia’s digestive ulcer drug market stood at about US$370 million as of 2021. HK inno.N aims to obtain approval for the drug in China within the first half of 2022. A review by Chinese authorities is under way.